title: Naturally occurring inhibitors against the formation of advanced glycation end-products.
abstract: Advanced glycation end-products (AGEs) are the final products of the non-enzymatic reaction between reducing sugars and amino groups in proteins, lipids and nucleic acids. Recently, the accumulation of AGEs in vivo has been implicated as a major pathogenic process in diabetic complications, atherosclerosis, Alzheimer's disease and normal aging. The early recognition of AGEs can ascend to the late 1960s when a non-enzymatic glycation process was found in human body which is similar to the Maillard reaction. To some extent, AGEs can be regarded as products of the Maillard reaction. This review firstly introduces the Maillard reaction, the formation process of AGEs and harmful effects of AGEs to human health. As AGEs can cause undesirable diseases or disorders, it is necessary to investigate AGE inhibitors to offer a potential therapeutic approach for the prevention of diabetic or other pathogenic complications induced by AGEs. Typical effective AGE inhibitors with different inhibition mechanisms are also reviewed in this paper. Both synthetic compounds and natural products have been evaluated as inhibitors against the formation of AGEs. However, considering toxic or side effects of synthetic molecules present in clinical trials, natural products are more promising to be developed as potent AGE inhibitors.
authors.affiliation: School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, P. R. China.
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Peng
authors.forename: Jinyu
authors.initials: J
authors.lastname: Ma
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Mingfu
authors.initials: M
authors.lastname: Wang
mesh_terms: D000375:Aging; D000544:Alzheimer Disease; D000818:Animals; D050197:Atherosclerosis; D001688:Biological Products / Q000494:pharmacology*; D048909:Diabetes Complications; D017127:Glycation End Products, Advanced / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D015416:Maillard Reaction
chemical_list: D001688:Biological Products; D017127:Glycation End Products, Advanced